Navalign LLC
NBIX icon

Navalign LLC’s Neurocrine Biosciences NBIX Stock Holding History

Navalign LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$258K Hold
1,818
– – 0.06% 109
2026
Q2 		$306K Sell
1,818
-1,251
-41% -$186K 0.07% 108
2026
Q1 		$404K Sell
3,069
-540
-15% -$71.6K 0.1% 97
2025
Q4 		$512K Hold
3,609
– – 0.13% 91
2025
Q3 		$507K Buy
+3,609
New +$489K 0.13% 90

Other funds holding NBIX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
IEQ Capital
IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Navalign LLC's NBIX Position: Q3 2026 in Review

Navalign LLC held its Neurocrine Biosciences (NBIX) position steady in Q3 2026 at 1,818 shares worth $258K. The position accounts for 0.06% of the portfolio, ranked #109.

Navalign LLC first reported a position in NBIX in Q3 2025 and has held it in 5 quarters since. The position peaked at $512K in Q4 2025. 446 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Navalign LLC held 1,818 shares of Neurocrine Biosciences worth $258K as of Q3 2026.
  • Navalign LLC left its Neurocrine Biosciences share count unchanged in Q3 2026.
  • Neurocrine Biosciences made up 0.06% of Navalign LLC's portfolio in Q3 2026, its #109 holding.
  • Navalign LLC first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 5 quarters since.
  • Navalign LLC's Neurocrine Biosciences position peaked at $512K in Q4 2025.
  • 446 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Navalign LLC's 13F filing for Q3 2026, filed 9 Nov 2026.